Eli Lilly stock recently achieved a significant milestone, reaching a 52-week high of $935.68, with shares now trading at $935.97. This marks a notable achievement for the pharmaceutical giant, ...

In a bid to boost oral medicine manufacturing capacity in Europe for patients worldwide, Lilly has confirmed plans to invest ...

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Company cuts 9,000 jobs and lowers profit forecast as Wegovy sales slow. Q3 operating profit down 30% on competition ...

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as sales growth ...

Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that ...

In late morning trade, the stock edged up by 1% in Copenhagen.